Navigation Links
Vical Licensee AnGes MG Announces Positive Results of Phase 3,Angiogenesis Trial in Japan

SAN DIEGO, June 18, 2007 /PRNewswire-FirstCall/ -- Vical Incorporated today announced that the company's licensee, AnGes MG, Inc. reported positive results following interim analysis of data from the first 41 subjects to complete a Phase 3 trial of an angiogenesis product candidate using Vical's DNA delivery technology. Based on the findings that the primary efficacy endpoint in the trial had been achieved with statistical significance and that there were no major safety concerns related to treatment, an Independent Data Monitoring Committee (IDMC) recommended stopping the trial early to prevent potential ethical issues against the placebo group subjects. AnGes is ending the trial and preparing to file an application for Japanese marketing approval.

"The successful Phase 3 results from our Japanese licensee position the AnGes product candidate to be the first approved for human use based on our DNA delivery technology and provide proof of concept for DNA delivery in the treatment of disease," said Vijay B. Samant, President and Chief Executive Officer of Vical. "This novel approach has the potential to address an important, unserved medical need in a significant commercial market. We look forward to further updates from AnGes as they advance through the regulatory approval process."

The treatment uses Vical technology to deliver a gene encoding Hepatocyte Growth Factor (HGF), a human protein that causes angiogenesis (growth of blood vessels) in areas of ischemia (restricted blood flow). In the trial, 40 subjects with critical limb ischemia (advanced peripheral arterial disease) were evaluated for efficacy. The primary endpoints, improvement of rest pain ((VAS (Visual Analog Scale)) or ischemic ulcer size, at 12 weeks post dosing, showed 30.8% improvement in the placebo group and 70.4% improvement in the treatment group, a statistically significant difference (p=0.014).

The following English
'"/>




Page: 1 2 3 4 5

Related medicine technology :

1. Vical Interim Clinical Results Demonstrate Safety and Tolerability of Inovio Biomedicals Electroporation DNA Delivery Technology
2. Vicals Vaxfectin Adjuvant With Needle-free Delivery Enhances DNA Vaccine Performance; Yields Antibody Responses Comparable to Electroporation Without Tolerability Issues
3. Vicals Vaxfectin Adjuvant Achieves Dose-Sparing Effect With Seasonal Influenza Vaccine
4. Geron Corp. Licensee TA Sciences Announces Landmark 7/07/07 Teleconference to Answer Questions About TA-65, Their Telomerase Activator With Proven Age Management Benefits
5. Antisoma Announces Further Data From ASA404 Ovarian Cancer Trial
6. Neose Announces Presentation of Positive Preclinical Data on GlycoPEGylated Factor VIIa at the XXI Congress of the International Society on Thrombosis and Haemostasis
7. Biofrontera AG Announces Clinical Study Confirms Excellent Efficacy of BF-200 ALA In Actinic Keratosis
8. YM BioSciences Announces Secondary Efficacy and Safety Findings in Randomized Phase IIB Aerolef Trial
9. BioSante Pharmaceuticals Announces New Findings for Potential Bird Flu Vaccine
10. Portola Pharmaceuticals Announces Positive Data from a Phase II Study of its Factor Xa Inhibitor at the XXI Congress of the International Society on Thrombosis and Haemostasis
11. Manhattan Pharmaceuticals Announces Results of Phase 2a Studies for Oral Oleoyl-estrone
Post Your Comments:
(Date:5/9/2008)...wire-USNewswire/ -- Osteoarthritis is a,painful an...almost 50,million people in the United States. It ...ints. The novel investigational pain medication,ta...ded significant relief,for patients with joint-dis... and with fewer gastrointestinal side effects than...
(Date:5/9/2008)...ire-FirstCall/ -- Ardea Biosciences, Inc.,(Nasdaq:...evelopment of,small- molecule therapeutics for the...s, including gout, today announced that John W. Be...ce and Operations and Chief,Financial Officer effe...of,directors shortly thereafter. The Company also ...
(Date:5/8/2008)...ire-FirstCall/ -- DATATRAK International, Inc.,(Na...ocused on global,eClinical solutions for the clini...results for the first quarter of 2008., For the t...d,approximately 41% to $2,088,000 and the Company ...r share on both a basic and diluted basis. These,r...
(Date:5/8/2008)...ort potential of asenapine in the treatment of ..., WASHINGTON, May 8 /- Sch...nced that an overview of asenapine clinical trials...st Annual Meeting of the,American Psychiatric Asso...e studies, involving patients with bipolar I disor...
Breaking Medicine Technology:Results of Phase 3 Study Show Tapentadol IR Relieves Acute Pain and Offers Favorable Gastrointestinal Tolerability Profile 2Results of Phase 3 Study Show Tapentadol IR Relieves Acute Pain and Offers Favorable Gastrointestinal Tolerability Profile 3Results of Phase 3 Study Show Tapentadol IR Relieves Acute Pain and Offers Favorable Gastrointestinal Tolerability Profile 4Results of Phase 3 Study Show Tapentadol IR Relieves Acute Pain and Offers Favorable Gastrointestinal Tolerability Profile 5Ardea Biosciences Appoints John W. Beck Chief Financial Officer, Announces Clinical Development Progress and Reports First Quarter 2008 Financial Results 2Ardea Biosciences Appoints John W. Beck Chief Financial Officer, Announces Clinical Development Progress and Reports First Quarter 2008 Financial Results 3Ardea Biosciences Appoints John W. Beck Chief Financial Officer, Announces Clinical Development Progress and Reports First Quarter 2008 Financial Results 4Ardea Biosciences Appoints John W. Beck Chief Financial Officer, Announces Clinical Development Progress and Reports First Quarter 2008 Financial Results 5Ardea Biosciences Appoints John W. Beck Chief Financial Officer, Announces Clinical Development Progress and Reports First Quarter 2008 Financial Results 6DATATRAK International Reports First Quarter Results for 2008 2DATATRAK International Reports First Quarter Results for 2008 3DATATRAK International Reports First Quarter Results for 2008 4DATATRAK International Reports First Quarter Results for 2008 5DATATRAK International Reports First Quarter Results for 2008 6DATATRAK International Reports First Quarter Results for 2008 7Overview of Asenapine Data from Olympia Trial Program Presented at American Psychiatric Association Annual Meeting 2Overview of Asenapine Data from Olympia Trial Program Presented at American Psychiatric Association Annual Meeting 3Overview of Asenapine Data from Olympia Trial Program Presented at American Psychiatric Association Annual Meeting 4Overview of Asenapine Data from Olympia Trial Program Presented at American Psychiatric Association Annual Meeting 5Overview of Asenapine Data from Olympia Trial Program Presented at American Psychiatric Association Annual Meeting 6Overview of Asenapine Data from Olympia Trial Program Presented at American Psychiatric Association Annual Meeting 7Challenge Tops 848 000 lbs Urges Oaklanders to Team Up to Fight Epidemic of Excess Weight 3878 1Challenge Tops 848 000 lbs Urges Oaklanders to Team Up to Fight Epidemic of Excess Weight 3878 2Challenge Tops 848 000 lbs Urges Oaklanders to Team Up to Fight Epidemic of Excess Weight 3878 3Challenge Tops 848 000 lbs Urges Oaklanders to Team Up to Fight Epidemic of Excess Weight 3878 4Actress and New Mom Keri Russell Joins PKIDs to launch Silence the Sounds of Pertussis Campaign 542 1Actress and New Mom Keri Russell Joins PKIDs to launch Silence the Sounds of Pertussis Campaign 542 2Actress and New Mom Keri Russell Joins PKIDs to launch Silence the Sounds of Pertussis Campaign 542 3A wheat for all seasons and reasons 846 1A wheat for all seasons and reasons 846 2A wheat for all seasons and reasons 846 3Bouncing bucky balls 1302 1Bouncing bucky balls 1302 2
...ewswire/ -- A nationally renowned,cancer researche...,presented a novel study design concept called a C...elerate new agent development.,Studies utilizing t...he network,s innovative Translational Oncology Pro...y phase trials in a community,setting. These types...
...WIRE)--Jun 5, 2007 - Synta,Pharmaceuticals Corp., ... on discovering, developing, and commercializing s...ions, today announced,it will hold a conference ca...ts, which will be presented at the annual meeting ...) in Chicago, Illinois,this morning., The conferen...
Other Medicine Technology:Study Shows Advantages of Complete Phase Ib Trial Over Separate,Phase I Trials 2Study Shows Advantages of Complete Phase Ib Trial Over Separate,Phase I Trials 3Study Shows Advantages of Complete Phase Ib Trial Over Separate,Phase I Trials 4Study Shows Advantages of Complete Phase Ib Trial Over Separate,Phase I Trials 5
(Date:5/9/2008)...rst Medication Indicated for Maintenance Treatment...all/ -- Eli Lilly and Company,(NYSE: LLY ) announ...inistration (FDA) has approved Strattera(R) (atomo...-Deficit/Hyperactivity Disorder (ADHD) in,children...hrine reuptake,inhibitor, is the first FDA-approve...
(Date:5/9/2008)...NGELES, May 9 /PRNewswire/ -- Los Angeles based Op...n Asia to assess the needs of what is now,an estim...ne which,destroyed or devastated wide swaths of My...ormerly the capital Rangoon) and throughout its va... of over 120 miles per hour and,struck communities...
(Date:5/9/2008)...tion for Iraq and Afghanistan Veterans Gather in V...eterans Service Organizations,, CHANTILLY, Va....raq,enters its fifth year and the U.S. death toll ...he 30,000 mark, a diverse coalition of military,an...have organized to help,bereaved families and wound...
(Date:5/9/2008)...ual demands reap mental benefits regardless of age...ay 9 (HealthDay News) -- Having an intellectually ... result in better cognitive abilities during retir... or age, a Duke University Medical Center study su...work longer than previous generations, so we sough...
Breaking Medicine News(10 mins):Health News:FDA Approves Strattera(R) for Maintenance of ADHD in Children and Adolescents 2Health News:FDA Approves Strattera(R) for Maintenance of ADHD in Children and Adolescents 3Health News:FDA Approves Strattera(R) for Maintenance of ADHD in Children and Adolescents 4Health News:FDA Approves Strattera(R) for Maintenance of ADHD in Children and Adolescents 5Health News:FDA Approves Strattera(R) for Maintenance of ADHD in Children and Adolescents 6Health News:Los Angeles Based Operation USA Appeals for Funds to Aid in Myanmar (Burmese) Cyclone Disaster (Updated) 2Health News:Leading Veterans Service Organizations Meet Near Washington May 13-15, 2008 2Health News:Leading Veterans Service Organizations Meet Near Washington May 13-15, 2008 3Health News:Leading Veterans Service Organizations Meet Near Washington May 13-15, 2008 4Health News:Demanding Jobs May Pay Cognitive Dividends in Retirement 2
...akash Hande and his colleagues from National Unive... exposure and risk of developing Chromosomal aberr...ers. The study is mainly aimed at identifying bio...tion of chromosome aberrations. The study is also ...
...different organs in our body is dependent upon a g...olved in the supply// of blood to different parts ...the coronary arteries. However, if there is a narr...hat supplies blood to the heart, the region of hea...
... using antiplatelet medication called clopidogrel ...the risk of death from cardiovascular problems lik...was published in the latest issue of JAMA. Dual an...ous coronary intervention using a combination of d...
...h fries seem to be entangled in a health controver...at acrylamide, a probable human cancer causing age...water set by the World Health Organization (WHO) b... Health said that measures have been taken to cont...
Other Medicine News:Health News:Cardiac bypass seems to be favoring men more than women 2Health News:Medicines Used In Antiplatelet Therapy Can Reduce Heart Attacks And Strokes 2Health News:French Fries In Cancer Controversy In China 2
...hermo Labsystems was designed specifically to comb...dvanced features such as the new fast dial system ...help to define this as a new leader in single chan... offers a custom fit for different hand sizes. The...
Super High Density, multi-frequency, phased array burr hole transducer. Excellent for taking biopsy samples and shunt placements.
Super High Density, multi-frequency, linear flexible laparoscopic transducer. ALOKA was the first company to introduce a flexible laparoscopic ultrasound transducer and, as a result, changed surgical
...lternative to the UST-995-7.5 for those surgeons w...n relation to the position of the transducer in th...frequency "T shaped convex intraoperative transduc...your index and middle fingers so that you can palp...
Medicine Products: